Prevalence and Real-World Clinical Outcomes of Hydroxyurea Resistance and Intolerance in Polycythemia Vera and Essential Thrombocythemia: A Single-Centre Experience
Related Experiment Videos
Waseem Shahani1, Kabeer Guriro2, Zaratulain Bashir1
1Department of Clinical Hematology, National Institute of Blood Disease and Bone Marrow Transplantation (NIBD & BMT), Plot #Special D-3 Block 6 PECHS, Karachi, Sindh Pakistan.
Abstract:
The clonal myeloid stem cell disorders, polycythemia Vera (PV) and essential Thrombocythemia (ET) are classified as Philadelphia chromosome negative myeloproliferative neoplasms (MPNs). The present study was done to evaluate the clinical response and survival outcomes of Hydroxycarbamide (HC) intolerance and resistance in adult PV and ET patients. A retrospective cohort study recruiting 81 patients was conducted at National Institute of Blood Diseases and Bone Marrow Transplantation (NIBD & BMT) from June 2012 to December 2024, and included patients of PV and ET who were treated with Hydroxycarbamide (HC) from 500 mg/day up to 3000 mg/day. Conventional risk stratification and European Leukemia Net (ELN) risk stratification criteria were implemented for PV and ET, respectively. Moreover, HC resistance or intolerance was evaluated using modified ELN (mELN) criteria. Out of 81 patients, 42 PV (51.9%) and 39 ET (48.1%) were evaluated. Higher median age was observed in PV as compared to ET (54.5 vs. 40 years). Consequently, risk stratification classified 33.3% of PV and 23.1% of ET patients to be high-risk. However, 23.0% and 4.3% of PV and ET patients with HC resistance transformed to myelofibrosis respectively. The prevalence of HC resistance was 30.9% in PV and 58.9% in ET, whereas HC intolerance was observed to be 26.1% in PV and 15.3% in ET. The patient's health improved significantly, as evident by a decline in active disease symptoms from 88.2% at baseline to 17.9% at 12 months.
Related Concept Videos
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Hemodialysis II: Procedure and Complications
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Hemodialysis I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Hypertension III: Clinical Manifestations and Diagnostic Studies